The Moo’D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood

Meghan Hockey†, Hajara Aslam†, Michael Berk1,2, Julie A. Pasco1,3,4,5, Anu Ruusunen1,6,7, Mohammadreza Mohebbi8, Helen Macpherson9, Mary Lou Chatterton1,10, Wolfgang Marx1, Adrienne O’Neil1, Tetyana Rocks1, Amelia J. McGuinness1, Lauren M. Young1 and Felice N. Jacka1*†

Abstract

Background: Beta-casein is a major protein in cow’s milk, of which A1 and A2 are the most frequent variants. Recent evidence implicates A1 beta-casein consumption in mechanisms that are of potential importance to mental health, yet its possible effects on psychological endpoints remains unknown. The primary aim of the study is to evaluate the comparative effects of consumption of dairy products containing A2 beta-casein versus conventional dairy (i.e. containing both A1 and A2 beta-casein) on symptoms of psychological distress in women with low mood.

Methods: The Moo’D Study is a 16-week, superiority, 1:1 parallel group, triple-blinded, randomised controlled trial. Ninety women with low mood (Patient Health Questionnaire score ≥ 5) will be randomised to consume either A2 beta-casein only or conventional dairy products. The primary outcome, symptoms of psychological distress, will be measured by the 21-item Depression, Anxiety and Stress Scale. Secondary outcomes will include symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness.

Discussion: This study will advance our understanding of the possible impact of milk proteins on psychological distress in women as well as elucidate mechanisms underpinning any association. Given dairy products form a substantial component of traditional and Western diets, the implications of these findings are likely to be of clinical and public health importance.

Trial registration: The trial protocol has been prospectively registered with the Australia and New Zealand Clinical Trials Registry, ACTRN12618002023235. Registered on 17 December 2018.

Keywords: Beta-casein, Milk, Dairy, Psychological distress, Inflammation, Gut microbiota, Depression, Psychiatry, Mental disorders, Randomised controlled trial

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Background and rationale

High prevalence mental disorders, such as depression and anxiety, are leading contributors to global disease burden and are associated with reduced quality of life and significant economic costs [1]. More generalised symptoms of psychological distress are widespread and at higher levels are estimated to affect one in eight (13%) Australians [2, 3]. As such, modifiable risk factors that may influence disease burden, such as dietary intake, have been the focus of recent research [4, 5].

Dairy products, including milk, yoghurt and cheese, are recommended as integral components of a high-quality diet and are also associated with broader health outcomes ranging from metabolic to mental disorders [6]. Recently, the role of dairy product consumption in mental disorders (i.e. depression and anxiety) has been the focus of increased research interest due to the potential of dairy products to interfere with biological pathways (e.g. inflammation) that have been implicated in these disorders [7, 8]. However, the relationship between dairy and depression has been reported inconsistently in epidemiological studies [9, 10]. For instance, milk consumption has been inversely associated with the risk of depressive symptoms in men [9], whereas milk consumption ≥ 250 mL/day of milk has been associated with an increased risk for de novo clinical depression in post-menopausal women [10]. Moreover, although studies have examined the differences in levels of dairy intake and fat composition on depression outcomes [11], none have considered the unique beta-casein profiles of dairy products, which may play a role in these differential associations. As such, the possible role of dairy in depression and anxiety, and its potential to influence biological pathways pertinent to these mental disorders, remains unclear.

Prior studies have attributed associations between the consumption of dairy products, particularly milk, and cardiovascular diseases and type 1 diabetes to a beta-casein protein variant present in milk [12, 13]. Beta-casein is a major protein component of cow’s milk, of which A1 and A2 beta-casein are two predominant types [14, 15]. Whilst A2 is thought to be the original beta-casein, a point mutation that occurred 5000–10,000 years ago in European herds produced the A1 variant [16]. The A1/A2 hypothesis was informed by these variations in amino acid sequences in beta-casein proteins and their subsequent biological effects [17]. Due to their structural variations, A1 and A2 proteins are digested differently in the gut by proteolytic enzymes; the A1 beta-casein fraction in milk produces a short opioid-like peptide, known as beta-casomorphine-7 (BCM-7), whilst the A2 beta-casein fraction yields minute quantities of BCM-7 [18].

A growing body of evidence also suggests that A1 beta-casein and BCM-7 are implicated in pathways that are believed important to the aetiology of mental disorders, including inflammation, oxidative stress and the gut microbiota [19, 20]. For example, two animal [21, 22] and three human [23–25] studies showed that administering A1 beta-casein isolates, or milk containing A1 beta-casein, increased humoral immune markers and other inflammatory markers. Concordantly, another study in humans reported that consumption of conventional milk containing A1 beta-casein was associated with reduced serum glutathione (GSH) levels compared to A2 milk [26]. Reductions in the antioxidant GSH can increase the inflammatory, oxidative and nitrosative stress burden, thus potentially exacerbating depressive symptoms [27]. In animal studies, BCM-7 increased gastrointestinal (GI) transit time via (mu) opioid receptor activity [28–30]. Prolonged transit time may perturb gut microbiota composition, which is believed to be of importance to mental disorders [31–33]. Moreover, pre-clinical evidence shows that BCM-7 influences brain regions and systems implicated in neurological conditions such as schizophrenia and autism [34]. Although there is a lack of clinical evidence examining the effect of A1 beta-casein on mood symptomology in humans, significantly elevated concentrations of BCM-7 have been observed in blood plasma [35, 36] and urine [37, 38] of patients with schizophrenia, autism and postpartum psychosis.

Specific objectives and hypothesis

Taken together, these findings suggest that A1 beta-casein consumption may have negative implications for mental health. However, a possible causal impact of A1 beta-casein consumption and symptoms of psychological distress has not been assessed in humans. Therefore, the primary aim of this randomised controlled trial is to evaluate the comparative effects of dairy products containing only A2 beta-casein, versus conventional dairy products that contain both A1 and A2 beta-casein proteins, on symptoms of psychological distress in women with low mood. This study will focus on women as we have previously shown that milk consumption is associated with an increased risk of de novo clinical depression in post-menopausal women [10]. Moreover, females experience higher rates of mood disorders compared to males [39]. The specific objectives are to:

1) Assess whether 16-week consumption of A2 beta-casein only dairy products will result in a reduction of psychological distress in women with low mood as assessed by mean change in the 21-item Depression Anxiety and Stress Scale (DASS-21) total score
at the completion of intervention phase, compared to conventional A1/A2 beta-casein dairy products.

(2) Assess the potential effects of 16-week consumption of A2 dairy products on symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness.

**Methods**

**Trial design and setting**

The Moo’D Study is a 16-week, superiority, parallel group, triple-blinded (i.e. participants, trial research team and study statistician), randomised, controlled trial conducted at the University Hospital Geelong, Australia. The study will randomise participants with 1:1 allocation ratio to either the intervention group (A2 beta-casein only dairy products) or the control group (conventional dairy products). The trial protocol has been prospectively registered with the Australia and New Zealand Clinical Trials Registry (ANZCTR; registered 17/12/18, ACTRN12618002023235) and was developed in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement [40]. The study has received ethical approval from the Barwon Health and Deakin University Human Research Ethics Committees (HREC) and will be conducted in accordance with the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP) and will be reported using the Consolidated Standards of Reporting Trials (CONSORT) statement [41].

**Eligibility criteria and recruitment**

Ninety women with low mood (score of ≥ 5 on the 8-item Patient Health Questionnaire; PHQ-8) will be recruited from the Greater Geelong and Melbourne regions. Table 1 provides the inclusion and exclusion criteria. Recruitment strategies may include a combination of online and community-based approaches such as social media posts (Facebook, Instagram, and Twitter); paid Google and Facebook advertisements; paid advertisements in local newspapers; free community talks on mental health; and displaying of flyers and pamphlets around Deakin University campuses, in places potential participants frequent (such as gyms, libraries and schools) and in clinics of general practitioners, psychologists and counsellors in the Greater Geelong region who are likely to consult with females with low mood. Study information will be listed on the study website (www.foodandmoodcentre.com/themoodstudy) and the Barwon Health Clinical Trial webpage. Trialfacts, an online recruitment service, will also be used to recruit and screen participants through social media campaigns and their existing patient database.

**Intervention and control**

Participants will be randomised to receive either A2 beta-casein only dairy products (intervention) or conventional dairy products containing both A1 and A2 beta-casein proteins (control). The intervention products (A2 beta-casein only dairy products) are naturally free of the A1 beta-casein protein but are otherwise nutritionally, visually and in taste and texture, equivalent to the control products (conventional dairy products). Beta-casein levels will be measured by an independent laboratory to determine the ratio of A1 and A2 beta-casein in investigational and control products. Both the intervention and control products will be prepared and packaged by the a2 Milk Company. The packaging for products will also be identical except for printed batch codes and expiry dates. Batch codes and expiry dates will be concealed as detailed in blinding procedures below.

**Table 1: Eligibility criteria**

| Inclusion criteria                                                                 | Exclusion criteria                                                                 |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| - Female                                                                          | - Current consumer of A2 dairy products                                         |
| - 18–75 years (at baseline)                                                       | - Cow’s milk (dairy) allergy (established diagnosis)                             |
| - Low mood (at baseline) as determined by a score of 5 or higher on PHQ-8         | - Lactose intolerance (established diagnosis)                                     |
| - Current conventional milk consumption of ≥ 250 ml serve/day                     | - Pregnant, planning to become pregnant, or lactating                            |
| - Willingness to commit to consuming only dairy products provided by the study    | - History of dementia and/or stroke                                              |
| - Available for intervention duration                                              | - Diagnosed with or commenced new treatment for, anxiety and/or depression, within 1 |
| - Able to understand study materials and directions, in English                   | - month prior to baseline                                                         |
| - Must have access to internet and a computer/smartphone/tablet                   | - GI diseases or past major GI surgery likely to interfere with study outcomes (e.g. ulcerative colitis, Crohn’s disease, faecal impaction, coeliac disease, herna colectomy, ileostomy, and colostomy) |
| - Be willing to comply with all requirements and procedures of the study          | - Regular use of morphine/opioid-based medications or recreational/illicit drugs |
| - Agree not to enrol in another interventional clinical research trial whilst part of the study | - Antibiotic use within the past month prior to baseline                         |

PHQ-8 Patient Health Questionnaire-8, GI, gastrointestinal
Participants in both the intervention and control arm will receive skim milk (ultra-heat treatment “UHT” milk) and full fat cheddar cheese (200 g block) according to their allocation (A2 or conventional dairy products). In accordance with dietary guidelines, reduced-fat products have been selected where available [42]. Participants in both the intervention and control arm will be advised to replace their usual milk and cheese with the study products and consume these in amounts they would normally consume (habitual consumption of at least 250 mL of study milk each day is an inclusion criterion). This is both to ease participant burden and enable examination of quantity of dairy consumed as a potential effect modifier. Participants in both the intervention and control arm will also be required to refrain from consuming all other cow’s milk products where protein makes a significant contribution to the overall nutritional composition, such as milk, yoghurt, cheese, kefir and mixed foods with dairy as a predominant ingredient, e.g. cream-based pasta sauces or dairy-based desserts. Otherwise, participants will be advised to maintain their usual diet. At study visit 1 (week 0), participants will receive dietary advice to aid with the selection of alternative products to replace those that are restricted within the intervention. For example, participants will be advised to consume goat’s or sheep’s yoghurt as a substitute for cow’s milk yoghurt, or to make their own yoghurt using the study products. These products are naturally free of the A1 beta-casein protein and are permitted to minimise unnecessary dietary restriction and aid with adherence to the intervention. Participants will also be advised that nutritional counselling is available throughout the study intervention should participants have difficulty adhering to the dietary intervention or if adherence results in undesirable weight changes.

Adherence
Adherence to the dietary prescription will be measured through the completion of hard-copy daily dairy diaries. Participants will be required to record how many serves of study milk and cheese they consume each day, to the nearest ½ serve. Consistent with the Australian Dietary Guidelines, a serve of milk has been defined as 250 mL and a serve of cheese as 40 g [42]. Food models will be used to educate participants on standard serve sizes. Additionally, participants are to complete an online questionnaire each week detailing the total number of serves of milk and cheese and any additional dairy products they consumed not provided by the study. To ensure that participants comply with the intervention, answers will be checked weekly by research personnel. Participants will be instructed to return their completed dairy diaries when they collect their study products. Adherence will be cross-checked with the data entered by participants online.

Randomisation
Following the completion of study visit 1, participants will be randomly assigned, on a 1:1 ratio, to receive either the A2 beta-casein only (A, intervention) or conventional dairy products (B, control) using stratified permuted block randomisation. Four strata will be constructed based on two variables: age (18–49, 50–75) and mood (PHQ-8 scores: 5–14; 15–24). An unblinded research assistant will use a computer-generated randomisation programme to generate a randomisation table using random block sizes, which will be partitioned by four strata based on the age and PHQ-8 scores.

Blinding
An unblinded research assistant will prepare four blinded ‘study kit’ allocation lists, one for each stratum. A random unique three-character alphanumeric study kit code (e.g. KL5, ZA1, CJ8) will be added in place of each group (A or B). The unblinded research assistant will make up study kits according to the group and label each with the appropriate kit code. This will ensure that study investigators, study statistician and participants will be blinded to the group allocation. The unblinded research assistant will not be involved in the analysis of study findings to preserve study blinding. Group allocations will only be available once all data collected have been entered into the study database for every participant and the database has been locked. Unblinding of intervention groups will only occur once statistical analysis is completed, except in the case of an emergency.

Implementation
Participants will be enrolled at study visit 1 by a blinded research assistant or investigator. After the completion of study visit 1, participants will be randomised by a blinded researcher and allocated a study kit code on a first-in-first-out assignment from the appropriate blinded ‘study kit’ allocation list depending on participant age and mood. A blinded research assistant or investigator will dispense study kits to participants according to the allocated study kit code. At each dairy collection visit, blinded researchers will dispense pre-packaged study kits to participants according to the allocated study kit code.

Participant timeline
Figure 1 provides a schematic diagram of enrolment, interventions and assessments. Participants will complete three study visits (weeks 0, 4, 16) in addition to completing fortnightly assessments online (see Table 2). Participants will also collect their dairy products at two of these visits (weeks 0 and 4) and return to the study centre to collect additional products at week 10.
Pre-screening
Potential participants will complete an online screening questionnaire. If eligible and willing to participate, they will be contacted by the study team to book their first study visit.

Study visit 1 (week 0)
At the commencement of study visit 1, participants will be re-screened against the eligibility criteria. If eligible, research personnel will ask participants to provide informed consent and will enrol participants in the study before the collection of any baseline measures. During this visit, participants will receive advice regarding the diet intervention and be provided with instructions on dairy storage, a hard-copy dairy diary to record their daily intake and a stool sample collection kit. Participants will also complete their baseline assessments, which include the collection of questionnaire data, a cognitive assessment, blood collection and a body composition scan (Table 2). On completion of study visit 1, participants will be randomised to either the intervention or control group. Participants will be required to return to the study centre within 72 h of their first study visit to collect their dairy products and return their completed stool sample.
Intervention period
Within 2 weeks of commencing the intervention, a study member will contact participants by phone to discuss adherence, trouble-shoot any difficulties encountered during the study period and book additional study visits.

In between clinical assessments, participants will complete online fortnightly self-report questionnaires and a weekly adherence questionnaire (see Table 2). The final (week 16) self-report questionnaires will be emailed to participants to complete online, to reduce burden and minimise time spent in-clinic.

Study visit 2 (week 4)
Participants will return their completed stool sample, provide a blood sample and collect additional study products.
**Dairy collection visit (week 10)**
Participants will return to the study centre to collect additional study products.

**Study visit 3 (week 16)**
Participants will return their completed stool sample and provide a blood sample. Participants will also complete a final cognitive assessment and body composition scan.

**Primary outcome measure**
The primary outcome is between-group differences from baseline to week 16 in symptoms of psychological distress, measured by total scores summed from the 21-item self-reported Depression Anxiety and Stress Scale (DASS-21). Questions on this scale pertain to feelings over the past week; however, to align with study assessment periods, participants will be required to rate how they were feeling in the past 2 weeks. Responses to each item are made on a 4-point scale from 0 (did not apply to me at all) to 3 (applied to me very much or most of the time), producing a maximum score of 63. Higher scores indicate more symptoms of dysphoric mood, whilst a score of 0 indicates the absence of disturbed mood symptoms rather than a positive mood state. Previous studies have demonstrated good validity and also high internal consistencies for all three subscales of the DASS-21 [43, 44].

**Secondary outcome measures**
Subscales of the DASS-21 (symptoms of depression, anxiety, stress individually) will be secondary outcomes. The 8-item Patient Health Questionnaire (PHQ-8) will be used as a screening measure to screen for low mood and will be administered fortnightly to measure changes in the severity of low mood. The PHQ-8 will also be used to measure changes in mood to detect any untoward changes in the severity of low mood throughout participants’ involvement in the trial.

Cognitive performance will be measured by a validated computerised cognitive brief battery, which has been used extensively in clinical trials, developed by Cogstate (Cogstate Ltd., Melbourne, Australia). The four tasks comprising the Cogstate Brief battery, from which main outcome variables will be analysed: Working Memory (One Back); Visual Learning (One Card); Psychomotor Function (Detection); and Attention (Identification). Additionally, the Paired Associate Learning (Continuous Paired Associate Learning) will be used as a measure of memory processes relating to encoding and retrieval [45, 46]. Both measures have acceptable construct and criterion validity in a neuropsychological context [47].

**Secondary outcome measures**
Subscales of the DASS-21 (symptoms of depression, anxiety, stress individually) will be secondary outcomes. The 8-item Patient Health Questionnaire (PHQ-8) will be used as a screening measure to screen for low mood and will be administered fortnightly to measure changes in the severity of low mood. The PHQ-8 will also be used to measure changes in mood to detect any untoward changes in the severity of low mood throughout participants’ involvement in the trial.

Cognitive performance will be measured by a validated computerised cognitive brief battery, which has been used extensively in clinical trials, developed by Cogstate (Cogstate Ltd., Melbourne, Australia). The four tasks comprising the Cogstate Brief battery, from which main outcome variables will be analysed: Working Memory (One Back); Visual Learning (One Card); Psychomotor Function (Detection); and Attention (Identification). Additionally, the Paired Associate Learning (Continuous Paired Associate Learning) will be used as a measure of memory processes relating to encoding and retrieval [45, 46]. Both measures have acceptable construct and criterion validity in a neuropsychological context [47].

The World Health Organization (WHO) WellBeing Index will be utilised to assess perceived wellbeing. Each statement is rated on a Likert scale (0–5) to assess how applicable they are to the participant’s feelings in the past 14 days. The total score indicates the level of wellbeing, which may range from an absence to maximal wellbeing [48].

The Athens Insomnia Scale will be utilised to assess sleep difficulty, quality and duration in the past month. It is an eight-item self-assessed psychometric instrument based on the WHO’s International Statistical Classification of Diseases and Related Health Problems (ICD-10) criteria [49].

Psychosocial aspects of quality of life will be assessed utilising the Assessment of Quality of Life (AQuoL)-8D, a Multi-Attribute Utility instrument developed by Monash University [49]. The instrument contains 35 items, which load onto eight dimensions. Three of these are related to a physical super-dimension (independent living, pain, senses) and the remaining five to a psychosocial super-dimension (mental health, happiness, coping, relationships and self-worth). The 35 items may be reduced to a single utility score using the AQuoL-8D algorithm, to reflect health-related wellbeing [49]. The utility values will also be used to calculate quality-adjusted life years (QALYs), a standard outcome measure in economic evaluations.

To determine participants’ broader use of healthcare services, a Resource Use Questionnaire (RUQ) will be completed at weeks 0 and 16. An economic evaluation will be undertaken as a cost consequences analysis from a primarily health sector perspective with an additional partial societal perspective included. The evaluation will measure and value the use of health care resources over the trial period for those in the intervention and control groups, and then compare any additional costs to the primary and secondary outcomes including QALYs. Medical resources collected through the RUQ will be costed using standard Australian unit costs (i.e. Medicare Benefits Schedule and Pharmaceutical Benefits Scheme). Lost work productivity, also captured in the RUQ, will be costed using the human capital approach by applying an average hourly wage rate plus 25% overhead costs [50, 51].

Functional GI disorders (e.g. irritable bowel syndrome, constipation, diarrhoea, and abdominal pain) will be assessed using the Rome IV Bowel Disorders and Central Nervous System Disorders of Gastrointestinal Pain Module, a sub-module of The Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults (R4DQ). This module contains questions from the R4DQ (Q: 40-67) and will be used to assess GI disorders in participants [52]. The Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS) questionnaire is a valid self-imaging tool that measure changes in GI symptoms in patients with IBS [53]. This tool will be
used to capture changes in gut symptomology (e.g., bloating, abdominal pain) in the intervention and control groups every fortnight. Participant’s stool formation will be assessed using the Bristol Stool Form Scale (BSFS) questionnaire every fortnight [54].

The gut microbiota will be assessed via stool samples using 16S rRNA gene sequencing. This technique is extensively used in identification of bacterial taxa in both animal and human faecal samples [55]. After sequencing, the 16S rRNA gene sequences will be matched to reference databases to identify operational taxonomic units corresponding to the genus or species level. In addition, subject to funding, stool samples may be sent for metagenomics analysis, an advanced and more in-depth analysis technique for assessing microbiota composition and inferred function [56].

Biomarkers of immune function and oxidative stress will be assessed via blood samples collected from participants. Markers of immune function (tumour necrosis factor-α, interleukin (IL)-1β, IL-6, IL-10) and gut inflammation (IL-4, humoral immune markers: immunoglobulin E, immunoglobulin G) will be analysed [57, 58]. Markers of endothelial integrity such as liposaccharide-binding protein (LBP) and CD14, which are indicators of microbial product dissemination to the peripheral circulation, will also be assessed [59, 60]. Changes in oxidative stress levels will be assessed using GSH, a marker of cellular redox balance [61]. Moreover, changes in metabolomic markers such as short-chain fatty acids (SCFA) and BCM-7 will be assessed. SCFA are metabolic by-products of microbial fermentation of dietary fibre in the gut and serve as markers of colonic health [62]. This study will measure SCFA concentrations in stool samples collected from participants, subject to funding. BCM-7 that are yielded by the enzymatic digestion of A1 beta-casein protein in milk will be measured in blood samples [61].

A whole body scan will be carried out using the dual energy X-ray absorptiometry (DXA, Lunar Prodigy Pro) to study body composition, which indicates fat, lean and bone mass of the participants [63].

Data will also be collected related to participant demographics, habitual diet using the Cancer Council’s Dietary Questionnaire for Epidemiological Studies v3.2 (DQES) [64], physical activity using the short form of the International Physical Activity Questionnaire (IPAQ) [65] and symptoms of personality disorders using the Standardised Assessment of Personality Abbreviated Scale (SAPAS) [66]. These variables will be examined as potential effect modifiers in exploratory post hoc subgroup analyses.

Adverse events
Adverse events (AE) will be monitored and recorded at all timepoints, which will be overseen by the study management team. Any unfavourable or unintended medical occurrence (e.g., sign, symptom, syndrome and illness) that develops or worsens during the trial will be reported as an AE. All AEs will be assessed for severity (mild, moderate, severe), causality (not related, unlikely, possibly, probably or definitely related to study treatment) and seriousness and will be documented by the study team. For any AE (regardless of seriousness or severity), researchers will maintain contact with participants until it has been resolved and symptoms disappear. If a participant experiences a significant AE, they may be withdrawn from the study. The decision will rest with the principal investigator and the participant will be referred to their treating doctor, if required. In the case of a serious adverse event (SAE), the HREC will be notified within 24 h of the researchers becoming aware of the event. Emergency unblinding will occur for an SAE deemed related to the study product.

Power calculation
To date, no studies have investigated the effects of A2 beta-casein only vs conventional dairy products on symptoms of psychological distress. For this reason, the anticipated effect size is largely based on findings derived from the broader nutrition literature [67–71]. A feasible sample size of 80 participants (40 per study arm) has been calculated to detect a medium intervention effect size of 0.63 (standard mean differences) defined as a between-group standard mean difference in DASS-21 total score from baseline to 16 weeks between the intervention and control groups. We assume the standard deviation of DASS-21 score change is 3.6, which is similar to published RCTs [67–69]. A sample size of 80 participants, achieves 80% power for a two-tailed analysis with a type I error level of 0.05 to detect a between-group mean difference of 2.3 or greater in DASS-21 total score from baseline to 16 weeks between the intervention and control groups. The total sample size will be inflated to 90 to account for an anticipated attrition rate of 12.5%. If our attrition rate is higher than anticipated (e.g. due to COVID-19 pandemic), we will aim to recruit further participants.

Statistical methods
All randomised participants with valid 0 and 16-week observations will be included in the primary analysis (modified intent-to-treat analysis). The primary outcome will be analysed using generalised estimating equation (GEE), using an identity link function and normal distribution, to test the between-group differential change in DASS-21 total score from baseline to 16 weeks follow-up between the intervention and control groups. This will be estimated through two-way interaction between group allocation and follow-up time points in a GEE.
model that includes nominal intervention allocation factor, nominal measurement time and the two-way interaction between allocation and measurement time. In order to account for within-participants’ autocorrelation due to repeated measurements, Huber/White cluster sandwich variance estimates will be used to account for clustering from the same study participants [72]. As a secondary analysis, an additional GEE model will be implemented that includes all observations with at least one post-baseline measure. All other secondary longitudinal continuous outcome analyses will follow the same method as the primary outcome analysis. Sensitivity analysis may be used to evaluate missing at random assumptions for missing follow-up data. This will be done by imputing data assuming missingness is positively or negatively associated with outcomes in the intervention and control group and then the intervention effect sizes will be estimated from these different imputation scenarios. An additional sensitivity analysis will be performed with a GEE model adjusted for baseline measurements as potential covariates. Exploratory post hoc subgroup analyses may also be conducted if feasible to explore possible moderation of intervention effects (e.g. menopause status). Cross-sectional associations of baseline demographic and prognostic variables (e.g. habitual diet, exercise, personality, biomarkers) will also be explored. This work will be independent to the main trial report and will be conducted subject to further funding and staff resourcing.

Data management, monitoring and dissemination
This research is led by investigators at Deakin University and is sponsored by Deakin University. The study sponsor is responsible for approving protocol amendments when ethics approvals have been obtained. In line with the ethical approval for this study, all data will be stored (re-identifiable) in a locked cabinet with secure-swipe card access, and on secure servers housed by Deakin University and Barwon Health. Access will be restricted to members of the study team only. All enrolled participants will be provided with a unique study ID number to protect the confidentiality of participants. Data and documentation relating to the study will be retained for at least 15 years. A data monitoring committee was not assembled due to the low-risk nature of the intervention and trial methods. On completion of the trial, participants will receive a report outlining the key study findings. Study investigators will also disseminate findings, presented as aggregate data only in the form of journal articles, conference presentations, seminars and community presentations. The funding body, a2 Milk Company, had no input into the design or conduct of the study and approval to publish the results of the study is not required.

Discussion
The existing body of evidence concerning dairy consumption and depression is inconsistent and equivocal, and lacks data on putative mechanistic pathways to explain previously observed outcomes [11]. By employing a rigorous triple-blinded, RCT design, this study will be the first to evaluate possible differential effects of A2 beta-casein only vs conventional dairy product consumption on symptoms of psychological distress. Through exploration of a range of secondary health outcomes, findings from this study will also expand our understanding of the biological effects of A1 and A2 beta-casein consumption in women and may provide novel insights into possible differential health effects of these dairy products.

A significant challenge with many dietary trials is blinding of the study intervention, which is important to minimise expectation bias [73]. A strength of this study is its triple-blind design; participants, the study statistician, researchers conducting study assessments and analysing study outcomes will be blinded to group allocation until completion of study analyses. Further, this study will have real-world applicability given that participants will consume dairy products in line with their usual intake and a range of A2 beta-casein products are widely available in mainstream food and grocery settings. Consideration has also been given to intervention duration; prior studies have indicated that dietary changes can affect depressive symptoms in as little as 3 weeks [71]; thus, the duration of the intervention (16 weeks) should be long enough for us to adequately examine the effects of beta-casein consumption on symptoms of psychological distress.

To summarise, this study will be the first to evaluate the possible differential effects of A2 beta-casein only vs conventional dairy consumption on symptoms of psychological distress. It will also expand our understanding of the biological effects of A1 and A2 beta-casein consumption and may provide novel insights into possible differential health effects of these dairy products in women with low mood. Findings from this study may have implications for the food industry, consumers and policy makers, particularly given the widespread consumption of dairy products. Further, outcomes from this study may empower consumers with knowledge to make informed choices in regard to selecting dairy products for consumption. This study will add to the growing evidence base in the field of Nutritional Psychiatry and facilitate our understanding of the possible role of milk-derived beta-casein proteins in human health.

Trial status
Recruitment for the RCT commenced in January 2019 and data collection was due to be completed by
December 2020. The trial was halted in March 2020 due to social distancing regulations in response to the COVID-19 global pandemic. The trial team plans to resume recruitment upon easing of COVID-19-related restrictions in 2021. Amendments to the protocol may be employed to minimise face-to-face contact with trial participants. Any amendments will be updated on the ANZCTR.

Protocol amendments

The trial Protocol is version 13 date 16/12/2019. The research ethics boards have approved changes to the protocol since inception of the trial. All changes have been updated in ANZCTR and communicated to relevant parties. Any further protocol amendments will be communicated with the ethics committee and any parties affected.

Abbreviations

ANZCTR: Australia and New Zealand Clinical Trial Registry; AQLQ: Assessment of Quality of Life; AE: Adverse events; BCM-7: Beta-casomorphine-7; BMI: Body mass index; BSFS: Bristol Stool Form Scale; CONSORT: Consolidated Standards of Reporting Trials; DASS-21: 21-item Depression Anxiety and Stress Scale; DQES: Dietary Questionnaire for Epidemiological Studies; DXA: Dual energy X-ray absorptiometry; GCP: Guidelines for Good Clinical Practice; GEE: Generalised estimating equation; GI: Gastrointestinal; HREC: Human Research Ethics Committees; ICD: International Statistical Classification of Diseases and Related Health Problems; IL: Interleukin; LBP: Lipopolysaccharide-binding protein; PHQ-8: 8-Item Patient Health Questionnaire; QALYs: Quality-adjusted life years; RCT: Randomised controlled trial; RUQ: Resource Use Questionnaire; R4DQ: The Rome IV Diagnostic Questionnaire for Functional Gastrointestinal Disorders in Adults; SAE: Serious adverse event; SAPAS: Standardised Assessment of Personality Abbreviated Scale; SCFA: Short-chain fatty acids; UHT: Ultra-heat treatment; VAS-IBS: The Visual Analogue Scale for Irritable Bowel Syndrome; WHO: World Health Organization

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05812-6.

Authors’ contributions

We would like to acknowledge the work of Catherine Helson in the early development of this trial. We would also like to thank Jessica Batti and Melissa Lane for their assistance with data collection. The authors thank Professor Graham Giles of the Cancer Epidemiology Centre of The Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies (Version 2), Melbourne: The Cancer Council Victoria 1996.

Acknowledgements

We would like to acknowledge the work of Catherine Helson in the early development of this trial. We would also like to thank Jessica Batti and Melissa Lane for their assistance with data collection. The authors thank Professor Graham Giles of the Cancer Epidemiology Centre of The Cancer Council Victoria, for permission to use the Dietary Questionnaire for Epidemiological Studies (Version 2), Melbourne: The Cancer Council Victoria 1996.

Additional file 1...

Additional file 2...

Investigational dairy products (intervention and control) for the duration of the study. The donors played no role in study design or data collection and will play no role in data analysis or reporting of the results. Donor: The a2 Milk Company Limited – NZ Co. No. 1014105, NZBN: 9429037368845. MH is supported by an Australian Rotary Health PhD Scholarship. HA is supported by Deakin University Postgraduate Industry Research Scholarship. MB is supported by a NHMRC Senior Principal Research Fellowship (1059660 and 1156072). HM is supported by a NHMRC-ARC Dementia training fellowship. Felice N Jacka is supported by an NHMRC Investigator Grant (#1194982). HA is supported by Deakin University Postgraduate Industrial Research Scholarship. AJM is supported by an Australian Rotary Health/Ten Island Tassie Tag Along Tour Funding Partner PhD Scholarship. WM is currently funded by an Alfred Deakin Postdoctoral Research Fellowship and a Multiple Schizophrenia Research Australia early-career fellowship. LMY is supported by an Australian Research Training Program Stipend. AO is supported by a Future Leader Fellowship (#101160) from the Heart Foundation Australia and Wilson Foundation.

Availability of data and materials

Data sharing does not apply to this manuscript as it is a protocol of an ongoing trial and no data are reported. Only trial investigators, who have been approved by ethics, will have access to the final trial dataset.

Declarations

Ethics approval and consent to participate

This study has received ethical approval from the Barwon Health (reference no. 17/169) and Deakin University Human Research Ethics Committees (reference no. 2018-234). Full ethical approval was granted on 28th November 2018, and for modifications made to the project since inception of the trial (see below). Informed consent will be obtained from participants at study visit 1 prior to enrolment in the study. Extended consent will also be sought for (1) the storage and use of data in future ethically approved research related to the same subject as the current study, (2) the storage and use of data in future research, any of type, that has been ethically approved and (3) to contact participants in regards to new research projects.

Consent for publication

No data pertaining to individual persons are included within this protocol. Model consent forms will be made available on request.

Competing interests

JAP has recently received Grant/Research support from the University of Melbourne, Deakin University, Barwon Health, Amgen-GSK OA-ANZBMS, Amgen Australia, the Geelong Community Foundation, the Norman Beischer Medical Research Foundation, the National Health and Medical Research Council (NHMRC) and the Medical Research Future Fund (MRFF). FNJ has received Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council (NHMRC), Australian Rotary Health, the Geelong Medical Research Foundation, the Ian Potter Foundation, Eli Lilly, Meat and Livestock Australia, Woolworths Limited, the Fernwood Foundation, Wilson Foundation, the A2 Milk Company, Be Fit Foods, and The University of Melbourne, and has received speakers honoraria from Sanofi-Synthelabo, Janssen Cilag, Servier, Pfizer, Health Ed, Network Nutrition, Angelini Farmaceutica, Eli Lilly and Metagenics. FNJ has written two books for commercial publication and has a personal belief that good diet quality is important for mental and brain health. MH has received research support from the A2 Milk Company. WM has previously received funding from the Cancer Council Queensland and university grants/fellowships from La Trobe University, Deakin University, University of Queensland, and Bond University, received industry funding and has attended events funded by Cobram Estate Pty, Ltd, received travel funding from Nutrition Society of Australia, received consultancy funding from Nutrition Research Australia, and has received speakers honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation. MLC has received Grant/Research support from NHMRC, University School of Health and Social Development, Deakin Health Economics, Institute for Health Transformation,icare Foundation, Medical Research Future Fund, Victorian medical research accelerator fund, beyondblue, Barwon Child, Youth & Family, and Medibank Health Research Fund. HM has received funding from the NHMRC National Institute for Dementia Research, Dementia Australia, and Australian Research
Council (ARC), LMY has previously received research funding from H&B Group. MB has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbott, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bioinformatics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier. TR has been supported by the Fernwood Foundation. TR has received grants, fellowships and research support from University of the Sunshine Coast, Australian Postgraduate Awards, Fernwood Foundation and Be Fit Food. TR received consultancy, honoraria and travel funds from Oxford University Press, the University of Melbourne, the University of Sydney, Bond University, University of Southern Queensland, Dietitians Association of Australia, Nutrition Society of Australia, The Royal Australian and New Zealand College of Psychiatrists, Academy of Nutrition and Dietetics, Black Dog Institute, Australian Rotary Health, Australian Disease Management Association, Department of Health and Human Services, Primary Health Networks, Barwon Health, West Gippsland Healthcare Group, Central West Gippsland Primary Care Partnership, Parkdale College, City of Greater Geelong and Global Age. AR has previously been supported by Postdoctoral Fellowship from Faculty of Health, Deakin University. MM has received Grant/research support from NHMRC, Deakin University School of Medicine, Deakin Biostatistics Unit, Institute for Mental and Physical Health and Clinical Translation, and Medibank Health Research Fund. AO has received research funding from National Health & Medical Research Council, Australian Research Council, University of Melbourne, Deakin University, Sanofi, Meat and Livestock Australia and Woolworths Limited and Honoraria from Novartis.

Author details
1The Food & Mood Centre, IMPACT (the Institute for Mental and Physical Health and Clinical Translation), School of Medicine, Barwon Health, Deakin University, Geelong, Australia. 2Oxygen, The National Centre of Excellence in Young Mental Health, Centre for Youth Mental Health, Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, The University of Melbourne, Melbourne, Australia. 3IMPACT (the Institute for Mental and Physical Health and Clinical Translation), School of Medicine, Barwon Health, Deakin University, Geelong, Australia. 4Department of Epidemiology and Preventive Medicine, Monash University, Prahran, VIC, Australia. 5Department of Medicine-Western Health, The University of Melbourne, St Albans, VIC, Australia. 6Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland. 7Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland. 8Biostatistics Unit, Faculty of Health, Deakin University, Burwood, VIC 3125, Australia. 9Institute for Physical Activity and Nutrition, Faculty of Health, Deakin University, Burwood, VIC 3125, Australia. 10Institute for Health Transformation, Faculty of Health, Deakin University, Geelong, Australia.

Received: 3 February 2021 Accepted: 9 November 2021

Published online: 11 December 2021

References
1. Whitelford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study 2010. PLoS One. 2015;10(2):e0116820. https://doi.org/10.1371/journal.pone.0116820.
2. Trautmann S, Rehm J, Wittchen HU. The economic costs of mental disorders. EMBO Rep. 2016;17(9):1245–9. https://doi.org/10.15252/embr.201542951.
3. Coombs T. Australian Mental Health Outcomes and Classification Network; Kessler-10 Training Manual. NSW Institute of Psychiatry. 2005.
4. Mann W, Moselle J, Berk M, Jacka F. Nutritional psychiatry: the present state of the evidence. Proc. Nutr. Soc. 2017;76(4):427–36. https://doi.org/10.1017/S002966511700206.
5. Lassale C, Baty GD, Baghdadi A, Jacka F, Sánchez-Villegas A, Kivimäki M, et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Mol Psychiatry. 2019; 24(7):965–86. https://doi.org/10.1038/s41380-018-0237-8.
6. Haug A, Hostmark AT, Harstad OM. Bovine milk in human nutrition—a review. Lipids Health Dis. 2007;6(1):25. https://doi.org/10.1186/1476-511X-6-25.
7. Ulven SM, Holven KB, Gil A, Rangel-Huerta OD. Milk and dairy product consumption and inflammatory biomarkers: an updated systematic review of randomized clinical trials. Adv Nutr. 2019;10(suppl_2):S239–50.
8. Moosavi SP, Rahimlou M, Saneei P. Esmaillzadeh A. Effects of dairy products consumption on inflammatory biomarkers among adults: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2020;30(6):872–88. https://doi.org/10.1016/j.numecd.2020.02.011.
9. Wolfe AR, Arroyo C, Tedders SH, Li Y, Dai Q, Zhang J. Dietary protein and protein- rich food in relation to severely depressed mood: a 10 year follow-up of a national cohort. Prog Neuro Psychopharmac Biol Psychiatry. 2011; 35(1):232–8. https://doi.org/10.1016/j.pnpbp.2010.11.011.
10. Pasco JA, Williams LJ, Brennan-Olsen SL, Berk M, Jacka FN. Milk consumption and the risk for incident major depressive disorder. Psychother Psychosom. 2015;84(6):384–6. https://doi.org/10.1519/000381831.
11. Hockey M, McGuinness AJ, Marx W, Rocks T, Jacka FN, Russuven A. Is dairy consumption associated with depressive symptoms or disorders in adults? A systematic review of observational studies. Crit Rev Food Sci Nutr. 2019; 60(21):1–16. https://doi.org/10.1080/10408398.2019.1703641.
12. Laugesen M, Elliott R. Ischaemic heart disease, Type 1 diabetes, and cow milk A1 β-casein. N Z Med J. 2003;116(1188):U205.
13. Elliott R, Harris D, Hill J, Bibby N, Wasmuth H. Type I (insulin-dependent) diabetes mellitus and cow milk casein variant consumption. Diabetologia. 1999;42(3):292–6. https://doi.org/10.1007/s001250051153.
14. Kaminski S, Cielinski A, Kostyra E. Polymorphism of bovine beta-casein and its potential effect on human health. J Appl Genet. 2007;48(3):189–98. https://doi.org/10.1007/s8196-007-0192-3.
15. ul Haq MR, Kapila R, Shandilya UK, Kapila S. Impact of milk derived β- caseinomers on physiological functions and trends in research: a review. Int J Food Prop. 2014;17(8):1726–41. https://doi.org/10.1080/10990039.2012.712077.
16. Pal S, Woodford K, Kulujean S, Ho S. Milk intolerance, beta-casein and lactose. Nutrients. 2015;7(9):2785–97. https://doi.org/10.3390/nu7097539.
17. De Noni I, FitzGerald RJ, Korhonen HI, Le Roux Y, Livesey CT, Thoroddt J, et al. Review of the potential health impact of β-caseinomers and related peptides. EFSA Sci Rep. 2009;21:1–107.
18. Brooke-Taylor S, Dwyer K, Woodford K, Kost N. Systematic review of the gastrointestinal effects of A1 compared with A2 β-casein. Adv Nutr. 2017; 8(5):739–48. https://doi.org/10.3945/an.116.13953.
19. Pereira JC, Rea K, Nolan YM, O'Leary OF, Dinan TG, Cryan JF. Depression’s unholy trinity: dysregulated stress, immunity, and the microbiome. Annu Rev Psychol. 2019;71.
20. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O’Neill A, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev. 2014;45:46–62. https://doi.org/10.1016/j.neubiorev.2014.05.007.
21. Haq MRU, Kapila R, Sharma R, Salganti V, Kapila S. Comparative evaluation of cow beta-casein variants (A1/A2) consumption on TH2-mediated inflammatory response in mouse gut. Eur J Nutr. 2014;53(4):1039–49. https://doi.org/10.1007/s00394-013-0606-7.
22. Haq MRU, Kapila R, Salganti V. Consumption of β-caseinomers-7/5 induce inflammatory immune response in mice gut through Th 2 pathway. J Funct Foods. 2014;8:150–60. https://doi.org/10.1016/j.jff.2014.03.018.
23. Ho S, Woodford K, Kulujian S, Pal S. Comparative effects of A1 versus A2 beta-casein on gastrointestinal measures: a blinded randomised cross-over pilot study. Eur J Clin Nutr. 2014;68(9):994–1000. https://doi.org/10.1038/ ejcn.2014.127.
24. Jiaqin S, Leining X, Lu X, Yelland GW, Ni J, Clarke AJ. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows’ milk. Nutr. J. 2016;15(1):35. https://doi.org/10.1186/s12937-016-0147-z.
25. He M, Sun J, Jiang ZQ, Yang YX. Effects of cow’s milk beta-casein variants on symptoms of milk intolerance in Chinese adults: a multicentre, randomised controlled study. Nutr J. 2017;16(1):2. https://doi.org/10.1186/s12937-017-0275-0.
26. Deth R, Clarke A, Ni J, Trivedi M. Clinical evaluation of glutatione concentrations after consumption of milk containing different subtypes of
beta-casein: results from a randomized, cross-over clinical trial. Nutr J. 2016; 15(1):82. https://doi.org/10.1186/s12937-016-0201-x.

27. Maes M, Kubera M, Leunis JC, Berk M, Geoffard M, Bosmans E. In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (OGSNS), and autoimmune responses directed against OGNs-damaged neoptopes. Acta Psychiatr Scand. 2013;127(5):344–54. https://doi.org/10.1111/j.1600-0447.2013.121908.x.

28. Becker A, Hempell G, Grecksch G, Matthies H. Effects of beta-casomorphin derivatives on gastrointestinal transit in mice. Biomed Bioch Acta. 1990; 49(11):1203–7.

29. Defilippi C, Gomez E, Charlin V, Silva C. Inhibition of small intestinal motility by casein: a role of beta casomorphin? Nutrition (Burbank, Los Angeles County, Calif). 1995;11(6):751–4.

30. Barnett MP, McNabb WC, Roy NC, Woodford KB, Clarke AJ. Dietary A1 β-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 β-casein in Wistar rats. Int J Food Sci Nutr. 2014;65(6):720–7. https://doi.org/10.3109/09639957.2014.898260.

31. Cheung S, Goldenthal AR, Uhlemann A-C, Mann JJ, Miller JM, Sublette ME. Systematic review of gut microbiota and major depression. Front Psych. 2012;2.14. https://doi.org/10.3389/fpsyg.2012.00034.

32. Mass M, Kubera M, Leunis J-C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuroendocrinol Lett. 2008;29(1):117–24.

33. Aslam H, Ruusunen A, Berk M, Loughman A, Rivera L, Pasco JA, et al. Economic evaluation of a dietary intervention for adults with major depression (the “SMILES” trial). BMC Public Health. 2018;18(1):599. https://doi.org/10.1186/s12889-018-5504-8.

34. Reichelt K, Ekrem J, Scott H. Gluten, milk proteins and autism: dietary derivatives on gastrointestinal transit in mice. Biomed Biochim Acta. 1990; 49(11):1203–1.

35. Lindström L, Nyberg F, Terenius L, Bauer K, Besev G, Gunne L, et al. CSF and plasma beta-casomorphin-like opioid peptides in postpartum psychosis. Am J Psychiatry. 1984;141(9):1059–66. https://doi.org/10.1176/ajp.141.10.1059.

36. Sun Z, Cade JR, Fregly MJ, Privette RM. Beta-Casomorphin induces Fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism, 1999;3(1):67–85. https://doi.org/10.1027/1601-9062.3.1.67.

37. Aslam H, Ruusunen A, Berk M, Loughman A, Rivera L, Pasco JA, et al. Unravelled facets of milk derived opioid peptides: a focus on gut pathology, fractures and obesity. Int J Food Sci Nutr. 2020;71(1):36–49. https://doi.org/10.1080/09639957.2019.1614540.

38. Chatterton ML, Chambers S, Occhipinti S, Girgis A, Dunn J, Carter R, et al. Economic evaluation of a psychological intervention for high distress cancer patients and carers: costs and quality-adjusted life years. Psycho-Oncology. 2016;25(2):1857–64. https://doi.org/10.1002/pon.4040.

39. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Taylor & Francis; 2017.

40. McGrew KS. CHC theory and the human cognitive abilities project: Standing out from the crowd. Intell. 2008;36(2):197–224. https://doi.org/10.1016/j.intell.2008.08.004.

41. Jankovic J, Hazell P, Aminoff MJ, Hallet M, Hallett M, Linn M, et al. Movement disorders in dementia. Neurology. 2006;66(1):30–7. https://doi.org/10.1212/01.wnl.0000195720.62691.d3.

42. Topp CW, Österdahl SD, Sandergaard S, Bech P. The WHO-S Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015; 84(3):167–76. https://doi.org/10.1159/000376585.

43. Antich MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess. 1998;10(2):176–81. https://doi.org/10.1037/1040-5959.10.2.176.

44. McGrew KS. CHC theory and the human cognitive abilities project: Standing on the shoulders of giants of psychometric intelligence research. USA: Woodcock-Muñoz Foundation, University of Minnesota, Elsevier; 2009. https://doi.org/10.1016/j.intell.2009.08.004.

45. Pang MP, Stough C. An evidence-based method for examining and reporting cognitive processes in nutrition research. Nutr Res Rev. 2014;27(2):232–41. https://doi.org/10.1017/S0955042140000150.

46. Maruff P, Thomas E, Cysyk L, Brew B, Collie A, Snyder P, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165–78. https://doi.org/10.1002/arclin.20310.

47. Antony MM, Bieling PJ, Cox BJ, Enns MW, Swinson RP. Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Stress Scales in clinical groups and a community sample. Psychol Assess. 1998;10(2):176–81. https://doi.org/10.1037/1040-5959.10.2.176.
64. Hodge A, Patterson AJ, Brown WJ, Ireland P, Giles G. The Anti Cancer Council of Victoria FFQ: relative validity of nutrient intakes compared with weighed food records in young to middle-aged women in a study of iron supplementation. Aust N Z J Public Health. 2000;24(6):576–83. https://doi.org/10.1111/j.1467-842X.2000.tb00520.x.

65. The International Physical Activity Questionnaire. Short Last 7 Days Self-Administered Format. 2002 [cited 2018 19 September]. Available from: http://www.ipaq.ki.se.

66. Fok MLY, Seegobin S, Frissa S, Hatch SL, Hotopf M, Hayes RD, et al. Validation of the standardised assessment of personality–abbreviated scale in a general population sample. Person Mental Health. 2015;9(4):250–7. https://doi.org/10.1002/pmh.1307.

67. Forsyth A, Deane FP, Williams P. A lifestyle intervention for primary care patients with depression and anxiety: a randomised controlled trial. Psychiatry Res. 2015;230(2):537–44. https://doi.org/10.1016/j.psychres.2015.10.001.

68. Macpherson H, Rowsell R, Cox K, Scholey A, Pipingas A. Acute mood but not cognitive improvements following administration of a single multivitamin and mineral supplement in healthy women aged 50 and above: a randomised controlled trial. Age. 2015;37(3):38. https://doi.org/10.1007/s11357-015-9782-0.

69. Harris E, Kirk J, Rowsell R, Vretta L, Sali A, Scholey AB, Pipingas A. The effect of multivitamin supplementation on mood and stress in healthy older men. Hum Psychopharmacol 2011;26(8):560-567, DOI: https://doi.org/10.1002/hup.1245.

70. Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohabbi M, et al. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Med. 2017;15(1):23. https://doi.org/10.1186/s12916-017-0791-y.

71. Francis HM, Stevenson RJ, Chambers JF, Gupta D, Newey B, Lim CK. A brief diet intervention can reduce symptoms of depression in young adults—a randomised controlled trial. PLoS One. 2016;11(10):e0162768. https://doi.org/10.1371/journal.pone.0162768.

72. Huber PJ, editor. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the fifth Berkeley symposium on mathematical statistics and probability; 1967: University of California Press.

73. Staudacher HM, Irving PM, Lomer MC, Whelan K. The challenges of control groups, placebos and blinding in clinical trials of dietary interventions. Proc Nutr Soc. 2017;76(3):203–12. https://doi.org/10.1017/S0029665117000350.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.